CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
2021年7月29日 - 9:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational conditionally activated therapeutics based on
its Probody® technology platform, today announced that it will
report second quarter 2021 financial results on Thursday,
August 5, 2021, after the close of U.S. markets. Following the
announcement, the Company will host a conference call and webcast
at 5:00 p.m. ET / 2:00 p.m. PT to discuss the
results and provide a corporate update.
Participants may access the live webcast of the
conference call from the Events and Presentations page of CytomX’s
website at www.cytomx.com. An archived replay of the webcast
will be available on the Company's website until August 12,
2021.
Audio Conference Call:
|
U.S. Dial-in Number: |
(877) 809-6037 |
|
|
|
|
International Dial-in Number: |
(615) 247-0221 |
|
|
|
|
Conference ID: |
1488138 |
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company with a vision of transforming lives with
safer, more effective therapies. We are developing a novel class of
investigational conditionally activated therapeutics, based on our
Probody® technology platform, for the treatment of cancer. CytomX
has strategic drug discovery and development collaborations with
AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody therapeutics are conditionally activated
biologics designed to remain inactive until they are activated by
proteases in the tumor microenvironment. As a result, Probody
therapeutics are intended to bind selectively to tumors and
decrease binding to healthy tissue, to minimize toxicity and
potentially create safer, more effective therapies. As leaders in
the field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential first-in-class therapeutic
candidates against novel, difficult to drug targets and potential
best-in-class immunotherapeutic candidates against clinically
validated targets. The CytomX clinical-stage pipeline comprises
five assets, four of which are in Phase 2 clinical studies.
First-in-class product candidates against previously undruggable
targets include a CD166-targeting conditionally activated
antibody-drug conjugate wholly owned by CytomX (praluzatamab
ravtansine, CX-2009) and a CD71-targeting conditionally activated
antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody-drug conjugates due to their
presence on many healthy tissues. The CytomX clinical-stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting Probodies,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and
our wholly-owned conditionally activated anti-PD-L1 antibody,
pacmilimab (CX-072). For additional information about CytomX
Therapeutics, visit www.cytomx.com and follow us on LinkedIn and
Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
Investor Contact:Chau Cheng,
PhD MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.com Direct: (650) 273-4999
Media Contact:Bret
CoonsDirector, Corporate Communicationsbcoons@cytomx.com Direct:
(650) 528 2929
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 9 2024 まで 10 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 10 2023 まで 10 2024